Skip to main content
Portfolio
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive183AccountSocial
MARKETSINVESTLIVE183
Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
  1. Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?



AI Digest · Compass Pathways says it finished its FDA application for COMP360 psilocybin

Not advice · 4d ago

Kalshi traders heavily favor drug developer Compass Pathways filing before December, and that view gained ground this week. Compass said on Monday it had completed its COMP360 application with the FDA, the US drug regulator. A Thursday report says the FDA is ending the priority voucher program that set a one to two month review target. The US health department has not confirmed it. Compass still expects a launch in the first half of 2027.

  • Psychiatric Times

    NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression

  • The Microdose

    FDA said to end speedy drug review program while Compass Pathways submits FDA New Drug Application for psilocybin; Feds commit $25 million for ibogaine and “psychotropic” research

Chance

95%

95%

98%

98%

98%

98%

3 more

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before December

Odds
97% chance
Max payout
Dec 1, 2026
$0
before April 2027
98%
before 2027
98%
before December
95%
0%25%50%75%100%MarMayJulSepNov
$41,670 vol
More Science and Technology Markets

Trending Science and Technology markets

Best AI at the end of 2026?Will the U.S. confirm that aliens exist?Anthropic market share this weekWhen will the Riemann hypothesis win the Millennium Prize?When will the Riemann Hypothesis be resolved?Will Anthropic announce a Millennium Prize solution?Open vs. Closed Token Volume (open weights share) todayOpen source share of spend today (Vercel)

Science and Technology hub

All Science and Technology markets